NEW YORK (GenomeWeb News) – Nxt2b has signed an agreement to purchase 49 percent of all outstanding shares of Swedish protein and molecular technologies firm Olink Bioscience for an undisclosed amount.
The deal is expected to "accelerate the growth and value creation of the company by injecting knowledge, experience, and financial strength to complement Olink's unique product and technology position," Olink said in a statement.
"Together with Nxt2b, we have now created a foundation to take Olink to new levels of commercial success by combining our unique portfolio of technologies and products with the experience and financial strength of Nxt2b," Olink President and CEO Björn Ekström said.
Nxt2b is a privately owned investment company owned by Bengt Ågerup that focuses on equity investments in medical devices, specialty pharmaceutical companies, and technology and consumer firms.